QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors

Male and female subjects ≥ 16 years of age with a diagnosis of EFT or DSRCT who have relapsed or progressed after at least one prior chemotherapeutic regimen will be eligible for this study. Before any study-specific procedure, the appropriate written informed consent must be obtained. Inclusion Criteria: Disease Related Subjects with pathological or histological diagnosis of Ewing's Family Tumor or Desmoplastic Small Round Cell Tumor. * Measurable disease as defined by RECIST. * Documented failure of at least one prior chemotherapy regimen for their disease. * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2. Demographic * Males or females ≥ 16 years old. * Signed written informed consent. * Able to comply with visits and procedures. Laboratory * Willing to provide existing and/or newly acquired tumor samples. * Diabetic Subjects (Type 1 or 2) must have HgbA1c \< 8.0% and fasting blood glucose level \< 160 mg/dL. General * Must be willing and able to use birth control (double barrier protection or abstinence) during and for 6 months after the study * Prior exposure to another anti-IGF-1R therapy will only be allowed for a limited number of additional subjects (up to 10) in an exploratory cohort Exclusion Criteria Disease Related * Known brain metastasis. * History of bleeding diathesis. * History of another malignancy. * History of chronic hepatitis. * Documented prior history of human immunodeficiency virus. Laboratory * Absolute neutrophil count \< 1.5 x109/L. * Platelet count \< 100 x 109/L. * Hemoglobin \< 9 g/dL. * PT \> 1.5 x institutional upper limit of normal (IULN) or PTT \> 1.0 x IULN. * Serum creatinine \> 1.5 x IULN. * Aspartate aminotransferase (AST) \> 2.5 x IULN or Alanine aminotransferase (ALT) \> 2.5 x IULN (\> 5.0 x if liver metastases present). * Total bilirubin \> 1.5 IULN (\> 3.0 x with documented Gilbert's Syndrome) Medication * Antitumor treatment within 21 days of Study Day 1. * Anticoagulation therapy within 28 days of Study Day 1. * Major surgery within 28 days of Study Day 1. General * Other investigational procedures are excluded. * Inability to tolerate intravenous administration. * Subject is pregnant (eg, positive HCG test) or is breast feeding.